Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Hewlett Packard Enterprise Co (HPE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Hewlett Packard Enterprise Co — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Hewlett Packard Enterprise Co trades at $44.76 (market cap $57.56B). The key difference: Hewlett Packard Enterprise Co is far larger — about 12.8× ACADIA Pharmaceuticals Inc.'s market cap, and Hewlett Packard Enterprise Co pays a 1.31% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | HPE | |
|---|---|---|
Market Cap | $4.49B | $57.56B |
Sector | Health | Technology |
52-Week High | $28.06 | $56.14 |
52-Week Low | $20.06 | $19.81 |
Enterprise Value | $3.69B | $73.52B |
Dividend Yield | — | 1.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
HPE trades at $43.445, up 5.42% today, with a bearish technical signal despite recent earnings beats. Revenue grew to $34.3B in 2025, but net income fell sharply to $57M, pressuring margins. Analysts show a mixed consensus with a $69.69 price target, implying significant upside. The stock faces headwinds from high valuation multiples and volatile cash flows, though AI server demand and dividend payments offer support.
The outlook balances growth from AI infrastructure investments against execution risks and margin pressure. Upside hinges on sustained earnings outperformance and debt management, while downside risks include competitive threats and macroeconomic volatility. Institutional sentiment is cautiously optimistic given the high price target disparity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →
